However, clinical studies evaluating the use of the anti-EGFR and anti-c-Met inhibitors in triple-negative breast cancer often demonstrate an initial response among a subset of patients followed by the development of treatment resistance [28,29]. The gene discussed is MET; the disease is triple-negative breast carcinoma.